Literature DB >> 15577674

Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion.

Hiroshi Inagaki1, Tsuneya Nakamura, Chunmei Li, Toshiro Sugiyama, Masahiro Asaka, Jyunichi Kodaira, Masahiro Iwano, Tsutomu Chiba, Kazuichi Okazaki, Atsunaga Kato, Ryuzo Ueda, Tadaaki Eimoto, Shiro Okamoto, Naomi Sasaki, Naomi Uemura, Taiji Akamatsu, Hideharu Miyabayashi, Yoko Kawamura, Hidemi Goto, Yasumasa Niwa, Takio Yokoi, Masao Seto, Shigeo Nakamura.   

Abstract

Gastric MALT lymphoma shows unique features including regression by Helicobacter pylori eradication and API2-MALT1 fusion. We performed a molecular and clinicopathologic study for 115 cases. All eradication-responsive cases were devoid of API2-MALT1 fusion. All tumors positive for the fusion and all negative for H. pylori infection were nonresponsive to the eradication. Consequently, gastric MALT lymphomas were divided into three groups: Eradication-responsive and fusion-negative (group A, n = 72), eradication-nonresponsive and fusion-negative (group B, n = 22), and eradication-nonresponsive and fusion-positive (group C, n = 21). Group A tumors were characterized by low clinical stage and superficial gastric wall involvement, and group C tumors by low H. pylori infection rate, advanced clinical stage, and nuclear BCL10 expression. All group C tumors showed exclusively low-grade histology. Group B tumors, which have not been well recognized, frequently showed nodal involvement, deep gastric wall involvement, and advanced clinical stage, and sometimes an increased large cell component. A multivariate discriminant analysis revealed that responsiveness to the eradication could be predicted accurately by negative API2-MALT1 fusion, positive H. pylori infection, low clinical stage, and superficial gastric wall invasion, the former being the most important factor for the prediction. This 3-group categorization may be helpful for a comprehensive understanding of gastric MALT lymphoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577674     DOI: 10.1097/00000478-200412000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  t (11;18)(q21;q21) chromosome translocation (A1446-M1150) of MALT lymphoma in buccal mucosa.

Authors:  Toshiaki Tanaka; Mituyoshi Iino
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-31       Impact factor: 4.553

Review 2.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Authors:  Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

3.  Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective.

Authors:  Seiji Shiota; Kazunari Murakami; Toshio Fujioka; Yoshio Yamaoka
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-04       Impact factor: 3.869

Review 4.  Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events.

Authors:  Sara Pereira da Silva; Elena Resnick; Mary Lucas; Jennifer Lortan; Smita Patel; Charlotte Cunningham-Rundles; Kevin Gatter; Qingyan Liu; Elaine S Jaffe; Helen Chapel
Journal:  J Clin Immunol       Date:  2011-07-09       Impact factor: 8.317

5.  Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication.

Authors:  Masaaki Kodama; Kazunari Murakami; Tadayoshi Okimoto; Ryugo Sato; Masahiro Uchida; Takashi Abe; Seiji Shiota; Yoshifumi Nakagawa; Kazuhiro Mizukami; Toshio Fujioka
Journal:  J Gastroenterol       Date:  2011-12-06       Impact factor: 7.527

Review 6.  Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up.

Authors:  Calogero Vetro; Alessandra Romano; Irene Amico; Concetta Conticello; Giovanna Motta; Amalia Figuera; Annalisa Chiarenza; Cosimo Di Raimondo; Giorgio Giulietti; Giacomo Bonanno; Giuseppe Alberto Palumbo; Francesco Di Raimondo
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

7.  Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT).

Authors:  Masahiro Tajika; Keitaro Matsuo; Hidemi Ito; Dai Chihara; Vikram Bhatia; Shinya Kondo; Tsutomu Tanaka; Nobumasa Mizuno; Kazuo Hara; Susumu Hijioka; Hiroshi Imaoka; Kazuya Matsumoto; Tsuneya Nakamura; Yasushi Yatabe; Kenji Yamao; Yasumasa Niwa
Journal:  J Gastroenterol       Date:  2013-06-25       Impact factor: 7.527

8.  Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type.

Authors:  Masahiko Ohtaka; Tadashi Sato; Shouji Kobayashi; Ryouta Sueki; Tatsuya Yamaguchi; Tomoyoshi Uetake; Hiroyuki Ohtsuka; Noriaki Iwao; Keita Kirito; Nobuyuki Enomoto
Journal:  Clin J Gastroenterol       Date:  2013-03-20

Review 9.  Helicobacter pylori: present status and future prospects in Japan.

Authors:  Hidekazu Suzuki; Toshifumi Hibi; Barry James Marshall
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

10.  Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach.

Authors:  Anke van Rijk; David Mason; Margaret Jones; José Cabeçadas; Mateus Crespo; Juan Cruz Cigudosa; Juan Fernando Garcia; Lorenzo Leoncini; Mario Cocco; Martin-Leo Hansmann; Anja Mottok; Christiane Copie Bergman; Maryse Baia; Dimitra Anagnostou; Evi Pouliou; Stephen Hamilton Dutoit; Mette Hjøllund Christiansen; Tim Svenstrup Poulsen; Steen Hauge Matthiesen; Jacques van Dongen; J Han van Krieken
Journal:  J Hematop       Date:  2008-08-29       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.